CN116270758A - 乳双歧杆菌ty-s01在控制体重方面中的新应用 - Google Patents
乳双歧杆菌ty-s01在控制体重方面中的新应用 Download PDFInfo
- Publication number
- CN116270758A CN116270758A CN202211474080.5A CN202211474080A CN116270758A CN 116270758 A CN116270758 A CN 116270758A CN 202211474080 A CN202211474080 A CN 202211474080A CN 116270758 A CN116270758 A CN 116270758A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- mice
- formulation
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 57
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 57
- 238000004260 weight control Methods 0.000 title abstract description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 40
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 17
- 210000000579 abdominal fat Anatomy 0.000 claims abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 9
- 238000004321 preservation Methods 0.000 claims abstract description 9
- 230000037396 body weight Effects 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 210000004185 liver Anatomy 0.000 claims description 34
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 16
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 239000006072 paste Substances 0.000 claims 1
- 235000011837 pasties Nutrition 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 210000005228 liver tissue Anatomy 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 70
- 230000001276 controlling effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 239000006041 probiotic Substances 0.000 description 10
- 235000018291 probiotics Nutrition 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 241000731710 Allobaculum Species 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241001657523 Coriobacteriaceae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000316163 Jeotgalicoccus Species 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001109789 Parvibacter Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 238000012896 Statistical algorithm Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- -1 compatibilizer Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 235000020192 probiotic milk Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于微生物应用技术领域,具体涉及一种乳双歧杆菌TY‑S01在控制体重方面中的新应用。该乳双歧杆菌TY‑S01的保藏编号为CGMCCNo.21255。该乳双歧杆菌TY‑S01可以显著降低机体的体重和腹部脂肪,显著降低肝脏组织中的甘油三酯和胆固醇水平,显著促进肠道分泌短链脂肪酸(乙酸)以及显著调节机体肠道菌群的紊乱,并且无任何毒副作用,安全性高。
Description
技术领域
本发明属于微生物应用技术领域,具体涉及一种乳双歧杆菌TY-S01在控制体重方面中的新应用。
背景技术
肥胖被定义为可能损害健康的异常或过量的身体脂肪堆积。据报道,世界上大约13%的成年人口受肥胖困扰。中国肥胖症工作组把成人超重定义为BMI为24.0kg/m2-27.9kg/m2,肥胖定义为BMI为大于等于28.0kg/m2。肥胖还易引发一系列代谢性疾病,如糖尿病、高血压、高血脂、脂肪肝等。另外,随着生活条件的不断改善,人们对健康的要求也逐渐严格,对自身体重的控制也越来越重视,因此各类减肥产品相继问世,但大多减肥产品安全性方面缺乏保障。
现有研究表明,肥胖与肠道菌群息息相关,肠道菌群的变化是引起肥胖的因素之一,健康人群和肥胖人群的肠道菌群具有显著差异。而且,现有人类和动物研究表明,益生菌可修复肠道菌群失调状态,从而达到控制宿主体重的效果;此外,多数肥胖人群伴有血脂升高的症状,而脂质(如胆固醇和甘油三酯)可在肝脏代谢,现有研究表明部分益生菌可通过调控肝脏脂质水平进而达到控制体重的效果;另外,益生菌的代谢产物同样具有控制体重的效果,比如短链脂肪酸,可通过激活相关受体抑制脂肪组织中的胰岛素信号,进而抑制脂肪堆积,从而控制宿主体重。所以,现目前也可以使用安全性高的益生菌代替现有安全性低的减肥产品进行体重控制。
因而,挖掘一种具有控制体重功效的益生菌具有重要意义。
发明内容
针对以上问题,本发明目的在于提供一种乳双歧杆菌(Bifidobacterium lactis)TY-S01在控制体重方面中的新应用,该菌种可以显著降低肝脏胆固醇和甘油三酯水平以及促进肠道分泌短链脂肪酸和调节肠道菌群紊乱从而达到控制体重的目的。
为了达到上述目的,本发明可以采用以下技术方案:
本发明提供一种乳双歧杆菌TY-S01在控制体重方面中的新应用,该乳双歧杆菌TY-S01的保藏编号为CGMCC No.21255。
本发明有益效果包括:本发明的乳双歧杆菌TY-S01可以显著降低机体的体重和腹部脂肪,显著降低肝脏组织中的甘油三酯和胆固醇水平,显著促进肠道分泌短链脂肪酸(乙酸)以及显著调节机体肠道菌群的紊乱,并且无任何毒副作用,安全性高。
附图说明
图1为各组小鼠摄食量曲线图;
图2为各组小鼠饮水量曲线图;
图3为各组小鼠体重增加量;
图4为各组小鼠腹部脂肪重量;
图5为各组小鼠饲料利用率;
图6为各组小鼠肝脏中甘油三酯水平;
图7为各组小鼠肝脏中胆固醇水平;
图8为各组小鼠粪便中丁酸水平;
图9为各组小鼠肠道菌群alpha多样性的chao指数;
图10为各组小鼠肠道菌群alpha多样性shannon指数;
图11为各组小鼠肠道菌群beta多样性;
图12为各组小鼠肠道菌群物种差异分析;
图中,实验数据以平均值±标准误(mean±SEM)表示;标有“*”、“**”、“***”、“****”均代表两组之间存在统计学差异,分别表示p<0.05、p<0.01、p<0.001、p<0.0001。
具体实施方式
所举实施例是为了更好地对本发明进行说明,但并不是本发明的内容仅局限于所举实施例。所以熟悉本领域的技术人员根据上述发明内容对实施方案进行非本质的改进和调整,仍属于本发明的保护范围。
本文中使用的术语仅用于描述特定实施例,并且无意于限制本公开。除非在上下文中具有明显不同的含义,否则单数形式的表达包括复数形式的表达。如本文所使用的,应当理解,诸如“包括”、“具有”、“包含”之类的术语旨在指示特征、数字、操作、组件、零件、元件、材料或组合的存在。在说明书中公开了本发明的术语,并且不旨在排除可能存在或可以添加一个或多个其他特征、数字、操作、组件、部件、元件、材料或其组合的可能性。如在此使用的,根据情况,“/”可以被解释为“和”或“或”。
本发明实施例提供一种乳双歧杆菌TY-S01在控制体重方面中的新应用,该乳双歧杆菌TY-S01的菌种保藏编号为CGMCC No.21255。需要说明的是,该乳双歧杆菌TY-S01来源于重庆天友股份有限公司,该菌株记载于专利202111569073.9中,该菌株的菌种保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),保藏编号为CGMCC No.21255,保藏日期为2020年11月27日。
需要说明的是,本发明中的乳双歧杆菌TY-S01不是特指乳双歧杆菌TY-S01活菌,也包括其灭活菌形态、裂解液形态、发酵液形态或者代谢物形态或者上述形态的混合形态,具体形态本领域技术人员可以根据具体需求进行选择。
在一些具体实施例中,上述应用包括:乳双歧杆菌TY-S01在制备降低体重的制剂中的应用。需要说明的是,在一些具体实施例中,使用了本发明中的乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的体重较没有使用乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的体重减少了约37%,即本发明中的乳双歧杆菌TY-S01在控制体重方面效果显著,且该乳双歧杆菌TY-S01没有影响小鼠模型的正常饮食,无任何毒副作用;还需要说明的是,乳双歧杆菌TY-S01可以通过减少腹部脂肪降低体重,在一些具体实施例中,使用本发明中的乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的腹部脂肪重量较没有使用乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的腹部脂肪重量减少了约21.8%。
在一些具体实施例中,上述应用包括以下一种或多种组合的应用:(a)乳双歧杆菌TY-S01在制备降低肝脏甘油三酯水平的制剂中的应用;(b)乳双歧杆菌TY-S01在制备降低肝脏胆固醇水平的制剂中的应用;(c)乳双歧杆菌TY-S01在制备促进肠道中短链脂肪酸分泌的制剂中应用;(d)乳双歧杆菌TY-S01在制备调节肠道菌群紊乱的制剂中的应用。
需要说明的是,上述应用中,使用本发明中的乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的肝脏甘油三酯水平较没有使用乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的肝脏甘油三酯水平下降了约32.3%,肝脏胆固醇水平下降了约10.2%;另外,乳双歧杆菌TY-S01可以显著调节高脂高胆固醇小鼠模型的肠道菌群紊乱情况。即本发明中的乳双歧杆菌TY-S01可以通过减少机体腹部脂肪、降低机体肝脏甘油三酯和胆固醇水平、促进机体肠道中短链脂肪酸的分泌以及调整机体肠道菌群紊乱从而达到控制体重的目的。
在一些具体实施例中,上述应用(d)中,短链脂肪酸可以为丁酸。需要说明的是,丁酸是短链脂肪酸中占比比较大的一种酸,其对脂肪组织的代谢和功能、能量和底物的代谢、系统性和特定组织的炎症、胰岛素敏感度和体重控制有积极影响,丁酸还能与肝脏和大脑等器官相互作用。在一些具体实施中,使用本发明中的乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的丁酸水平提较没有使用乳双歧杆菌TY-S01的高脂高胆固醇小鼠模型的丁酸水平提高1倍以上。
在一些具体实施例中,上述应用中,制剂包括食品制剂或药物制剂。需要说明的是,本发明中的制剂不特指药物制剂,即可以将本发明中的乳双歧杆菌TY-S01添加药用载体或可食用载体制备成药物制剂或可食用食物制剂,可以根据具体临床情况,具体选择药用或者食用。
在一些具体实施例中,上述应用中,制剂包括固体剂型、液体剂型、膏状剂型或乳状剂型。需要说明的是,可以将本发明中的乳双歧杆菌TY-S01添加固体剂型辅料制备成固体剂型,比如片剂和丸剂,固体剂型辅料为本领所已知的,一般包括稀释剂(如淀粉、糊精、蔗糖或甘糖等)、吸收剂(硫酸钙、磷酸氢钙或轻质氧化镁等)、粘合剂(聚维酮、糖浆或羟丙甲纤维素等)、润湿剂(水等)或崩解剂(干淀粉、羟甲基淀粉钠或交联聚维酮等)等;在一些具体实施例中,固体剂型可以是益生菌片、益生菌丸或益生菌颗粒;同上,还可以将本发明中的乳双歧杆菌TY-S01添加液体剂型辅料(比如增容剂、助悬剂、乳化剂或着色剂等)制备成液体剂型(比如益生菌饮料);还可以添加膏状剂型辅料制备成膏状剂型(比如益生菌果冻、益生菌奶盖或凝固型酸奶等);还可以添加乳状剂型辅料(比如果胶)制备成乳状剂型(比如搅拌型酸奶)。具体的剂型,本领域技术人员可以根据具体需求进行选择。
为了更好地理解本发明,下面结合具体示例进一步阐明本发明的内容,但本发明的内容不仅仅局限于下面的示例。
以下实施例中,乳双歧杆菌TY-S01来源于重庆天友股份有限公司,该菌株记载于专利202111569073.9中,该菌株的菌种保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),保藏编号为CGMCC No.21255,保藏日期为2020年11月27日。
以下实施例中,MRS液体培养基来自北京陆桥技术股份有限公司。
实施例
一、菌株的培养及处理
取﹣80℃冻存甘油保藏的菌株,按2%的接种量接种到5mL的添加了0.05%的半胱氨酸的MRS液体培养基中,置于37℃厌氧培养72h,菌株活化3代;活化好的菌液在4℃下,10000r/min,离心10min,弃去上清液,收集菌体。菌体用生理盐水洗涤,再次离心,重复两次,得到菌泥,再用12%的脱脂乳溶液重悬,真空冷冻干燥冻干后得菌粉,于﹣20℃保存,用于动物实验灌胃;使用前用生理盐水梯度稀释,并利用倾注法对活菌数进行计数,计算菌落形成单位(CFU)。根据计数结果用生理盐水调整菌液浓度至109CFU/mL,得灌胃用菌悬液。
二、动物验证实验
(1)实验小鼠分组及干预
选取SPF级野生型雄性C57BL/6小鼠10只和SPF级雄性ApoE-/-小鼠20只,均为8周龄;饲养于室温25±2℃、相对湿度50±5%、12h光照/12h黑暗的标准化实验室中,适应性喂养一周后开始实验;适应期结束后,C57BL/6小鼠为空白组,ApoE-/-小鼠随机分为模型组和TY-S01组,每组10只。
实验周期为42天,期间空白组小鼠摄入普通饲料,模型组、TY-S01组小鼠摄入高脂高胆固醇饲料,具体配方如表1所示;另每日对所有组别小鼠进行灌胃操作,空白组和模型组小鼠灌胃生理盐水(200μL),TY-S01组灌胃上述菌悬液(200μL),每天灌胃时间保持一致。
表1高脂高胆固醇饲料配方表
成分 | 克 | 千卡 |
酪蛋白 | 200 | 800 |
L-光氨酸 | 3 | 12 |
玉米淀粉 | 212 | 848 |
麦芽糖糊精 | 71 | 284 |
蔗糖 | 113 | 452 |
纤维算BW200 | 50 | 0 |
大豆油 | 25 | 225 |
可可油 | 155 | 1395 |
混合矿物质S10021 | 10 | 0 |
碳酸氢钙 | 13 | 0 |
碳酸钙 | 5.5 | 0 |
柠檬酸钾 | 16.5 | 0 |
混合维生素V10001 | 10 | 40 |
酒石酸氢胆碱 | 2 | 0 |
胆固醇 | 11.25 | 0 |
蓝色染料 | 0.05 | 0 |
黄色染料 | 0.05 | 0 |
红色染料 | 0 | 0 |
总量 | 897.35 | 4056 |
(2)实验期间小鼠生长性能监测
记录上述(1)中小鼠实验周期42天内每天小鼠的体重、摄食量及饮水量,并以周为单位按照以下公式测定饲料利用率(%),
实验期间小鼠摄食量及饮水量变化统计图具体如图1和图2所示,在整个实验期间,模型组和TY-S01组小鼠的摄食量及饮水量与正常组相比无显著变化,小鼠的摄食量变化及饮水量变化能在一定程度上反映其健康状况,所以图1和图2可以表明高脂高胆固醇饲料未影响小鼠的正常生活及生长,且表明乳双歧杆菌TY-S01无任何毒副作用。
各组小鼠的增重量如图3所示,实验期间空白组小鼠摄入普通饲料,模型组和TY-S01组小鼠则摄入高脂高胆固醇饲料,为期42天的实验干预期,空白组小鼠增重3.52g,模型组小鼠增重5.33g,模型组较之空白组显著增重更多(p<0.001),而TY-S01组小鼠增重3.36g,较之模型组增重显著降低(p<0.0001)。
(3)小鼠样本收集及处理
实验周期持续42天,之后牺牲小鼠,牺牲小鼠前一天小鼠禁食不禁水16h,并收集小鼠粪便于离心管,立即液氮冷冻后-80℃冰箱保存;取小鼠腹部脂肪称重并记录;解剖小鼠分离肝组织和肠组织,立即液氮冷冻后-80℃冰箱保存。
各组小鼠的腹部脂肪如图4所示,实验结束时空白组小鼠腹部脂肪为0.35g,模型组小鼠腹部脂肪为0.55g,模型组较之空白组显著增加57.1%(p<0.01),而TY-S01组小鼠腹部脂肪为0.43g,较之模型组降低21.8%。
为期6周的实验周期中,所有组别小鼠饲料利用率(饲料利用率反映小鼠摄食量和体重增加量之间的比值)逐渐降低,模型组小鼠饲料利用率始终高于空白组,且两组走势相当;TY-S01组小鼠饲料利用率第1周时与空白组接近,随着实验进行TY-S01组逐渐低于空白组,且差距逐渐拉大,如图5所示。
以上结果说明,乳双歧杆菌TY-S01具有控制体重的功效。
(4)小鼠肝脏脂质水平测定
取出上述(3)中冷藏的肝脏,切取并准确称量0.5g,加入5mL甲醇与氯仿混合液(体积比2:1),用组织匀浆机(60HZ,匀浆时间10s/次,间隙30s,连续5次,在4℃下进行)充分研磨,使肝脏组织匀浆化;完全磨碎后将研磨混合液转至刻度试管内,并用4.5mL甲醇与氯仿混合液(体积比2:1)冲洗研磨器,洗涤液一并转至刻度试管,将前后两次收集的匀浆混合液定容至10mL,置于水浴锅45℃温浴1小时,然后8000g,10min,4℃离心收集上清液,用全自动生化仪检测胆固醇和甘油三酯水平(脂类可分为脂肪和类脂两类,脂肪包括甘油三脂,类脂包括胆固醇;甘油三脂易在脂肪堆积,过高甚至有患脂肪肝的风险;肝脏是脂质代谢的中心,人体内70%-80%的胆固醇由肝脏合成;因此检测肝脏脂质水平具有重要意义)。
各组小鼠的肝脏甘油三酯水平如图6所示,空白组小鼠肝脏甘油三酯水平为5.56μmol/g,模型组为7.86μmol/g,模型组较之空白组肝脏甘油三酯水平显著升高(p<0.001),而TY-S01组小鼠肝脏甘油三脂水平为5.32μmol/g,较之模型组显著降低(p<0.001)。
各组小鼠的肝脏胆固醇水平如图7所示,空白组小鼠肝脏胆固醇水平为2.24μmol/g,模型组为8.64μmol/g,模型组较之空白组肝脏胆固醇水平显著升高(p<0.0001),而TY-S01组小鼠肝脏胆固醇水平为7.76μmol/g,较之模型组有所降低。
以上结果说明,乳双歧杆菌TY-S01具有调控肝脏脂质水平的功效。
(5)气相色谱法检测小鼠粪便中的短链脂肪酸含量
取50mg小鼠粪便样品加入500μL饱和NaCl溶液,振荡至无明显块状物(组织破碎仪,60HZ,匀浆时间10s/次,间隙30s,连续5次,在4℃下进行),加入40μL 10%硫酸酸化,振荡混匀,随后加入1000μL的乙醚萃取,振荡混匀,12 000rpm、15min、4℃条件下离心,取上清加入到装有0.25g的无水硫酸钠的EP管中,静置15min,同样条件离心,取上清加入气相小瓶,上机分析,气相色谱检测条件如下表2所示。
表2气相色谱检测条件表
利用气相色谱法检测小鼠粪便中丁酸的含量,短链脂肪酸浓度通过外标法计算。短链脂肪酸是人体自身无法消化的碳水化合物经肠道细菌发酵后产生的最终代谢产物,包括乙酸、丙酸、异丁酸、丁酸、异戊酸和戊酸等,其中90%以上的短链脂肪酸为乙酸、丙酸和丁酸。短链脂肪酸有助于进行管理健康和体重管理,例如免疫调节和排毒。有研究表明,丁酸对脂肪组织的代谢和功能、能量和底物的代谢、系统性和特定组织的炎症、胰岛素敏感度和体重控制有积极影响,丁酸还能与肝脏和大脑等器官相互作用。
各组小鼠粪便丁酸水平如图8所示,空白组小鼠粪便丁酸水平为129.8μg/g,模型组为29.0μg/g,模型组较之空白组粪便丁酸水平显著降低(p<0.0001),而TY-S01组小鼠粪便丁酸水平为62.1μg/g,较之模型组显著升高(p<0.05)。
以上结果说明,乳双歧杆菌TY-S01具有促进肠道短链脂肪酸分泌的功效。
(6)小鼠粪便菌群多样性分析
取出上述(3)中冷藏的肠组织,分离出盲肠内容物;根据soil DNA试剂盒的说明书进行盲肠内容物微生物群落总DNA抽提,使用1%的琼脂糖凝胶电泳检测DNA的提取质量,NanoDrop 2000用于测定DNA浓度和纯度;使用338F(5’-ACTCCTACGGGAGGCAGCAG-3’)和806R(5’-GGACTACHVGGGTWTCTAAT-3’)对16S rRNA基因V3-V4可变区进行PCR扩增,扩增程序如下:95℃预变性3min,25个循环(95℃变性30s,55℃退火30s,72℃延伸45s),然后72℃稳定延伸10min,最后在4℃进行保存(PCR仪:ABI/>9700型);PCR反应体系为:5×TransStart FastPfu缓冲液4μL,2.5mM dNTPs 2μL,上游引物(5μM)0.8μL,下游引物(5μM)0.8μL,TransStart FastPfu DNA聚合酶0.4μL,模板DNA10ng,ddH2O补足至20μL。
将同一样本的PCR产物混合后使用2%琼脂糖凝胶回收PCR产物,利用AxyPrep DNAGel Extraction Kit进行回收产物纯化,2%琼脂糖凝胶电泳检测,并用QuantusTMFluorometer对回收产物进行检测定量;使用NEXTflexTM Rapid DNA-Seq Kit进行建库:(1)接头链接;(2)使用磁珠筛选去除接头自连片段;(3)利用PCR扩增进行文库模板的富集;(4)磁珠回收PCR产物得到最终的文库;利用Illumina公司的NovaSeq PE250平台进行测序,测序委托上海美吉生物医药科技有限公司完成。
肠道微生物群可通过与宿主之间的一系列分子相互作用促进宿主胰岛素抗性,低度炎症和脂肪沉积,间接参与宿主体重调控。人体和动物模型的研究,均已证明肠道微生物群因肥胖而改变。本发明实施例对小鼠肠道菌群进行多样性分析,进一步探究乳双歧杆菌TY-S01对肠道菌群的调节作用。
alpha多样性分析是微生物多样性分析中一个重要的组成部分,主要用于研究某一样本的菌群多样性;Chao指数是alpha多样性指数中的一种,其用chao1算法估计样品中所含OTU数目,反映群落丰富度。
各组小鼠的Chao指数如图9所示,空白组小鼠Chao指数为516.0,模型组为114.5,模型组较之空白组粪便丁酸水平显著降低(p<0.0001),而TY-S01组小鼠Chao指数为189.5,较之模型组有所升高。shannon指数则是反映样本各物种均一性的一种alpha多样性指数,反映群落多样性。
各组小鼠的Shannon指数如图10所示,空白组小鼠Shannon指数为3.68,模型组为2.32,模型组较之空白组粪便丁酸水平显著降低(p<0.0001),而TY-S01组小鼠Chao指数为2.85,较之模型组显著升高(p<0.05)。
以上结果说明,体重增重导致了小鼠肠道菌群丰富度和多样性的降低,而乳双歧杆菌TY-S01一定程度上恢复了肠道菌群的丰富度和多样性。
beta多样性分析是微生物多样性分析中一个重要的组成部分,主要用于研究不同样品间的微生物多样性。该分析将样品间的物种丰度分布差异程度通过统计学中的距离进行量化分析,使用统计算法计算两两样品间距离,获得距离矩阵,并将其进行可视化统计分析。
本发明实施中采用Bray-Curtis算法,结果如图11所示,图中不同形状的数据点代表着各组小鼠的肠道菌群样本,数据点越靠近代表两个样本的肠道菌群越相似;其中,空白组和模型组相隔甚远、完全没有重叠部分,说明较之空白组,模型组小鼠肠道菌群组成发生很大程度上的改变,而TY-S01组较之模型组同样相隔一定距离,说明乳双歧杆菌TY-S01对小鼠肠道菌群具有一定程度的调节作用。
物种差异分析利用不同的组间差异检验方法,根据得到的群落丰度数据,运用统计学方法对不同组微生物群落之间的物种进行假设检验,评估物种丰度差异的显著性水平,获得组间显著性差异物种,结果如图12所示,较之空白组,模型组属水平上Allobaculum、Coriobacteriaceae_UCG-002、Parvibacter、Escherichia-Shigella物种丰度显著上升(p<0.05),而乳双歧杆菌TY-S01显著抑制了这种上升趋势(p<0.05);Corynebacterium、Staphylococcus、Jeotgalicoccus、Lachnospiraceae_UCG-006、unclassified_c__Bacilli、unclassified_k__norank_d__Bacteria物种丰度显著降低(p<0.05),而乳双歧杆菌TY-S01显著抑制了这种下降趋势(p<0.05)。
以上结果说明,乳双歧杆菌TY-S01可以调节因体重增加导致的肠道菌群紊乱。
综上所述,乳双歧杆菌TY-S01可以同时减少腹部脂肪、降低肝脏中甘油三酯和胆固醇水平、促进肠道中短链脂肪酸分泌以及调整肠道菌群紊乱,实现协同降低体重。
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的宗旨和范围,其均应涵盖在本发明的权利要求范围。
Claims (8)
1.乳双歧杆菌(Bifidobacteriumlactis)TY-S01在控制体重方面中的新应用,乳双歧杆菌TY-S01的保藏编号为CGMCCNo.21255。
2.根据权利要求1所述的新应用,其特征在于,应用包括:乳双歧杆菌TY-S01在制备降低体重的制剂中的应用。
3.根据权利要求2所述的新应用,其特征在于,应用包括:乳双歧杆菌TY-S01在制备减少腹部脂肪的制剂中的应用。
4.根据权利要求1所述的新应用,其特征在于,应用包括以下一种或多种组合的应用:(a)乳双歧杆菌TY-S01在制备降低肝脏甘油三酯水平的制剂中的应用;(b)乳双歧杆菌TY-S01在制备降低肝脏胆固醇水平的制剂中的应用;(c)乳双歧杆菌TY-S01在制备促进肠道中短链脂肪酸分泌的制剂中应用;(d)乳双歧杆菌TY-S01在制备调节肠道菌群紊乱的制剂中的应用。
5.根据权利要求4所述的新应用,其特征在于,应用(c)中,短链脂肪酸为丁酸。
6.根据权利要求1至5中任一权利要求所述的新应用,其特征在于,制剂包括食品制剂或药物制剂。
7.根据权利要求1至5中任一权利要求所述的新应用,其特征在于,制剂包括固体剂型、液体剂型、膏状剂型或乳状剂型。
8.根据权利要求6中所述的新应用,其特征在于,制剂包括固体剂型、液体剂型、膏状剂型或乳状剂型。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211474080.5A CN116270758A (zh) | 2022-11-22 | 2022-11-22 | 乳双歧杆菌ty-s01在控制体重方面中的新应用 |
NL2035197A NL2035197B1 (en) | 2022-11-22 | 2023-06-28 | Use of bifidobacterium lactis ty-s01 in human body weight control |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211474080.5A CN116270758A (zh) | 2022-11-22 | 2022-11-22 | 乳双歧杆菌ty-s01在控制体重方面中的新应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116270758A true CN116270758A (zh) | 2023-06-23 |
Family
ID=86815534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211474080.5A Pending CN116270758A (zh) | 2022-11-22 | 2022-11-22 | 乳双歧杆菌ty-s01在控制体重方面中的新应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116270758A (zh) |
NL (1) | NL2035197B1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116590205A (zh) * | 2023-07-14 | 2023-08-15 | 中国农业大学 | 一种动物双歧杆菌亚种组合菌剂在减肥制剂制备中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113142303A (zh) * | 2021-01-18 | 2021-07-23 | 重庆市天友乳业股份有限公司 | 一种具有预防肥胖功效的酸奶及其制备方法 |
CN113142301B (zh) * | 2021-01-18 | 2023-08-08 | 重庆市天友乳业股份有限公司 | 一种可提高机体免疫力的乳制品及其制备方法 |
CN114568703A (zh) * | 2022-02-24 | 2022-06-03 | 重庆市天友乳业股份有限公司 | 一株乳双歧杆菌的新用途 |
-
2022
- 2022-11-22 CN CN202211474080.5A patent/CN116270758A/zh active Pending
-
2023
- 2023-06-28 NL NL2035197A patent/NL2035197B1/en active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116590205A (zh) * | 2023-07-14 | 2023-08-15 | 中国农业大学 | 一种动物双歧杆菌亚种组合菌剂在减肥制剂制备中的应用 |
CN116590205B (zh) * | 2023-07-14 | 2023-10-03 | 中国农业大学 | 一种动物双歧杆菌亚种组合菌剂在减肥制剂制备中的应用 |
Also Published As
Publication number | Publication date |
---|---|
NL2035197A (en) | 2023-07-27 |
NL2035197B1 (en) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240000871A1 (en) | Lactobacillus gasseri capable of alleviating and treating hyperuricemia | |
CN112574917B (zh) | 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 | |
TWI673057B (zh) | 新穎副乾酪乳桿菌(Lactobacillus paracasei)株 | |
TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
CN114181864B (zh) | 一种鼠李糖乳杆菌hf01及其应用 | |
CN114507621A (zh) | 一株植物乳杆菌及在降尿酸、减重、抗炎症方面的应用 | |
CN109593678B (zh) | 长双歧杆菌yh295及其在制备降低腹型肥胖风险产品中的应用 | |
CN111164201B (zh) | 用于改善代谢症候群的副干酪乳杆菌gks6、其用途、医药组合物及可食用组合物 | |
CN115992059B (zh) | 一株产阿魏酸酯酶的约氏乳杆菌及其缓解溃疡性结肠炎的用途 | |
WO2018112739A1 (zh) | 一种假小链状双歧杆菌及其培养方法和应用 | |
CN113797232B (zh) | 具有缓解胰岛素抵抗功能的组合物及其应用 | |
CN116270758A (zh) | 乳双歧杆菌ty-s01在控制体重方面中的新应用 | |
CN115887485A (zh) | 茯苓多糖对肥胖机体肠道微生物结构及其代谢产物的调节应用 | |
CN110810629A (zh) | 益生菌制剂及其应用 | |
CN117866798A (zh) | 发酵乳杆菌glf-217及其在溃疡性结肠炎、高脂血症和降低器官损伤中的应用 | |
CN110684682B (zh) | 缓解pfoa毒害作用的多功能干酪乳杆菌ccfm1052、其发酵食品及应用 | |
CN113249256B (zh) | 一株缓解雌激素相关代谢紊乱及肥胖的植物乳杆菌及应用 | |
CN112236154A (zh) | 一种组合物及其应用 | |
CN113215029A (zh) | 一种约氏乳杆菌及其应用 | |
CN113444669B (zh) | 一株植物乳杆菌Lactobacillus plantarum F3-2及其应用 | |
NL2035207B1 (en) | Application of lactobacillus paracasei in preparation for reducing serum cholesterol levels | |
CN118028190B (zh) | 发酵粘液乳杆菌bas313及其在制备降血糖产品中的应用 | |
CN116004442A (zh) | 一种发酵乳杆菌及其在改善高脂血症制剂中的应用 | |
CN115786216B (zh) | 一种酸鱼乳杆菌zjuf yj5及其应用 | |
CN117562189B (zh) | 维生素k在制备调控肉鸡肠道菌群饲料中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |